tbuckley/cabot-search huggingface dataset:
Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
Authors: Emilie Le Rhun, Fabian Wolpert, Maud Fialek, Patrick Devos, Nicolaus Andratschke, Nicolas Reyns, Reinhard Dummer, Laurent Mortier, Michael Weller
Journal: Journal of Clinical Oncology (2020)

2532 Background: The evaluation of response in the context of treatment with stereotactic radiotherapy (SRT) or immune checkpoint inhibitors (ICI) or both, which represent major therapeutic options for patients with melanoma brain metastases, remains challenging due to potential tumor hemorrhage, pseudoprogression, and radionecrosis. Methods: We reviewed clinical and neuroimaging data of 62 melanoma patients, including 26 patients with BRAF-mutant tumors, with newly diagnosed brain metastases treated with immune checkpoint inhibitors (ICI) alone (n = 10, group 1), SRT alone or in combination with other systemic therapies (n = 20, group 2) or ICI plus SRT (n = 32, group 3). Response was assessed retrospectively using RECIST 1.1, RANO or iRANO criteria. Results: The MRI scans of 52 patients were available for central review. Patients received steroids at BM diagnosis in 10% in group 1, 60% in group 2 and 50% in group 3. Pseudoprogression was documented in 7 patients: 3 patients in group 2 (19%) and 4 patients (12%) in group 3. Radionecrosis was documented in 7 patients: 2 patients in group 2 (12%) and 5 patients (16%) in group 3. Patients treated with ICI alone had the worst outcome. Using RANO criteria by central review instead of local investigator assessment increased the rate of progressive disease (PD) as best response for the evaluation of SRT targets but not for the evaluation of the overall brain. Using complete RANO (including clinical assessment and steroid use) instead of RECIST criteria increased the rate of PD as best response, due to clinical deterioration noted in patients with MRI findings that did not qualify for PD. This pattern was seen in patients from all three groups. In contrast, the complete response (CR) rate was unaffected by the criteria used. More PD were also observed when comparing MRI only iRANO criteria versus complete iRANO criteria including clinical status and steroid use. Conclusions: Pseudoprogression is uncommon with ICI alone, suggesting that growing lesions in such patients should trigger an intervention. Pseudoprogression rates were similar after SRT alone or in combination with ICI. Response assessment criteria should be considered carefully when designing clinical studies for patients with brain metastases who receive SRT.
Risk Factors Associated With COVID-19 Related Anosmia And Ageusia
Authors: Esha Sehanobish, Mali Barbi, Valerie Fong, Meryl Kravitz, Cynthia Matsumura, Denise Tejera, Mohammad Asad, Denisa Ferastraoaru, Meaghan O'Neill, Merhunisa Karagic, Nadeem Akhbar, Danielle Bottalico, Viraj Patel, Golda Hudes, Mimi Kim, Ruth Eisenberg, Avindra Nath, Bryan Smith, Thomas Ow, Elina Jerschow
Journal: Journal of Allergy and Clinical Immunology (2021)

Anosmia and ageusia are associated with COVID-19 in addition to other symptoms. In this study we examined factors associated with anosmia and ageusia and their recovery in an ethnically diverse cohort in Bronx, NY, and assessed the overall rate of anosmia and ageusia and their associations with other COVID-19 related symptoms. Individuals tested for SARS-CoV-2 at Montefiore Medical Center were included in the study. Those who consented from a randomly selected subsample and answered the questionnaire were included in the analysis. Overall, 33% and 50% of COVID-19 patients (N=486) reported anosmia and ageusia, respectively, and 58% reported both. Those with reported anosmia and ageusia more often had systemic symptoms (fever, body aches, fatigue), respiratory symptoms (cough, sore throat), and diarrhea, compared to those without anosmia or ageusia (p-value<0.01). Patient characteristics associated with lower probability of anosmia and ageusia included older age (AOR(anosmia):0.980, 95% CI:0.967-0.993, p-value<0.01, AOR(ageusia):0.98, 95%CI:0.970-0.990, p-value<0.01) and higher peripheral eosinophil count (AOR(anosmia):0.021, 95%CI:0.001-0.460, p-value=0.01, AOR(ageusia):0.10, 95%CI:0.010-0.970, p-value<0.05). Male gender was independently associated with a lower probability of ageusia (AOR:0.56, 95%CI:0.380-0.820, p-value<0.01) and a better recovery from ageusia (AHR:1.44, 95%CI:1.05-1.98, p-value<0.05). Latinos too had better ageusia recovery than the whites (AHR:1.82, 95%CI:1.05-3.18, p-value<0.05). COVID-19 patients with anosmia and ageusia are more likely to report greater presence of systemic, respiratory, and gastrointestinal symptoms. Older patients and those with higher blood eosinophil counts are less likely to report anosmia and ageusia. Men have a lower probability of reporting ageusia and men and Latinos recover faster from it.
Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows
Authors: Jacqui Wise
Journal: BMJ (2021)

Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows Jacqui WiseThe anti-inflammatory treatment, tocilizumab, improves survival for patients hospitalised with covid-19, shortens the time to discharge, and reduces the need for a mechanical ventilator, results from the randomised evaluation of covid-19 therapy (Recovery) trial show. 1 1
Association of Headache With School Functioning Among Children and Adolescents in the United States
Authors: Scott B. Turner, Christina L. Szperka, Andrew D. Hershey, Emily F. Law, Tonya M. Palermo, Cornelius B. Groenewald
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Abstract 14349: Sacubitril/Valsartan Reduces All-Cause Mortality and Hospitalizations in HFrEF Patients in a Belgian Real-Life Clinical Setting
Authors: Tahnee Sente, Ruth Van Landuyt, Marie-Anne Van Lierde, Stefaan Vancayzeele, Michael Maris
Journal: Circulation (2019)

Introduction: The PARADIGM-HF trial demonstrated that sacubitril/valsartan (S/V) was superior to enalapril in reducing hospitalizations for heart failure, cardiovascular death and all-cause mortali...
Serum food-specific Immunoglobulin G4 (sIgG4) levels decrease after steroid treatment in Eosinophilic Esophagitis (EoE)
Authors: Rung-chi Li, Behnam Keshavarz, Jeffrey Wilson, Lisa Workman, Barrett Barnes, Bryan Sauer, Thomas Platts-Mills, Emily McGowan
Journal: Journal of Allergy and Clinical Immunology (2021)
A spinal organ of proprioception for integrated motor action feedback
Authors: Laurence D. Picton, Maria Bertuzzi, Irene Pallucchi, Pierre Fontanel, Elin Dahlberg, E. Rebecka Björnfors, Francesco Iacoviello, Paul R. Shearing, Abdeljabbar El Manira
Journal: Neuron (2021)

Proprioception is essential for behavior and provides a sense of our body movements in physical space. Proprioceptor organs are thought to be only in the periphery. Whether the central nervous system can intrinsically sense its own movement remains unclear. Here we identify a segmental organ of proprioception in the adult zebrafish spinal cord, which is embedded by intraspinal mechanosensory neurons expressing Piezo2 channels. These cells are late-born, inhibitory, commissural neurons with unique molecular and physiological profiles reflecting a dual sensory and motor function. The central proprioceptive organ locally detects lateral body movements during locomotion and provides direct inhibitory feedback onto rhythm-generating interneurons responsible for the central motor program. This dynamically aligns central pattern generation with movement outcome for efficient locomotion. Our results demonstrate that a central proprioceptive organ monitors self-movement using hybrid neurons that merge sensory and motor entities into a unified network.
Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021
Authors: Radhika Gharpure, Angela Guo, Courtney Krier Bishnoi, Urvi Patel, David Gifford, Ashley Tippins, Aaron Jaffe, Evan Shulman, Nimalie Stone, Elisabeth Mungai, Suparna Bagchi, Jeneita Bell, Arjun Srinivasan, Anita Patel, Ruth Link-Gelles
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Residents and staff members of long-term care facilities (LTCFs), because they live and work in congregate settings, are at increased risk for infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1,2). In particular, skilled nursing facilities (SNFs), LTCFs that provide skilled nursing care and rehabilitation services for persons with complex medical needs, have been documented settings of COVID-19 outbreaks (3). In addition, residents of LTCFs might be at increased risk for severe outcomes because of their advanced age or the presence of underlying chronic medical conditions (4). As a result, the Advisory Committee on Immunization Practices has recommended that residents and staff members of LTCFs be offered vaccination in the initial COVID-19 vaccine allocation phase (Phase 1a) in the United States (5). In December 2020, CDC launched the Pharmacy Partnership for Long-Term Care Program* to facilitate on-site vaccination of residents and staff members at enrolled LTCFs. To evaluate early receipt of vaccine during the first month of the program, the number of eligible residents and staff members in enrolled SNFs was estimated using resident census data from the National Healthcare Safety Network (NHSN†) and staffing data from the Centers for Medicare & Medicaid Services (CMS) Payroll-Based Journal.§ Among 11,460 SNFs with at least one vaccination clinic during the first month of the program (December 18, 2020-January 17, 2021), an estimated median of 77.8% of residents (interquartile range [IQR] = 61.3%- 93.1%) and a median of 37.5% (IQR = 23.2%- 56.8%) of staff members per facility received ≥1 dose of COVID-19 vaccine through the Pharmacy Partnership for Long-Term Care Program. The program achieved moderately high coverage among residents; however, continued development and implementation of focused communication and outreach strategies are needed to improve vaccination coverage among staff members in SNFs and other long-term care settings.
Erythrocyte membrane-camouflaged carrier-free nanoassembly of FRET photosensitizer pairs with high therapeutic efficiency and high security for programmed cancer synergistic phototherapy
Authors: Xuanbo Zhang, Jianchen Xiong, Kaiyuan Wang, Han Yu, Bingjun Sun, Hao Ye, Zhiqiang Zhao, Ning Wang, Yuequan Wang, Shenwu Zhang, Wutong Zhao, Haotian Zhang, Zhonggui He, Cong Luo, Jin Sun
Journal: Bioactive Materials (2021)

Phototherapy has been intensively investigated as a non-invasive cancer treatment option. However, its clinical translation is still impeded by unsatisfactory therapeutic efficacy and severe phototoxicity. To achieve high therapeutic efficiency and high security, a nanoassembly of Forster Resonance Energy Transfer (FRET) photosensitizer pairs is developed on basis of dual-mode photosensitizer co-loading and photocaging strategy. For proof-of-concept, an erythrocyte-camouflaged FRET pair co-assembly of chlorine e6 (Ce6, FRET donor) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR, FRET acceptor) is investigated for breast cancer treatment. Notably, Ce6 in the nanoassemby is quenched by DiR and could be unlocked for photodynamic therapy (PDT) only when DiR is photobleached by 808-nm laser. As a result, Ce6-caused phototoxicity could be well controlled. Under cascaded laser irradiation (808–660 nm), tumor-localizing temperature rise following laser irradiation on DiR not only induces tumor cell apoptosis but also facilitates the tumor penetration of NPs, relieves tumor hypoxia, and promotes the PDT efficacy of Ce6. Such FRET pair-based nanoassembly provides a new strategy for developing multimodal phototherapy nanomedicines with high efficiency and good security.
Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating
Authors: Longfa Xu, Qingbing Zheng, Rui Zhu, Zhichao Yin, Hai Yu, Yu Lin, Yuanyuan Wu, Maozhou He, Yang Huang, Yichao Jiang, Hui Sun, Zhenghui Zha, Hongwei Yang, Qiongzi Huang, Dongqing Zhang, Zhenqin Chen, Xiangzhong Ye, Jinle Han, Lisheng Yang, Che Liu, Yuqiong Que, Mujin Fang, Ying Gu, Jun Zhang, Wenxin Luo, Z. Hong Zhou, Shaowei Li, Tong Cheng, Ningshao Xia
Journal: Cell Host & Microbe (2021)
Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients
Authors: E. Steve Woodle, John S. Gill, Stephanie Clark, Darren Stewart, Rita Alloway, Roy First
Journal: JAMA Surgery (2021)

The complications of corticosteroids make the inclusion of these drugs in immunosuppressive protocols for kidney transplant patients undesirable. However, cessation of corticosteroids is associated with a higher risk of short-term rejection, and the long-term outcomes of patients withdrawn from corticosteroids remain uncertain.To compare long-term kidney transplant outcomes of patients randomized to continue or withdraw corticosteroids.This prospective multicenter randomized double-blind placebo-controlled trial was conducted between November 1999 and December 2002 with linkage to a mandatory national registry with validated outcome ascertainment until June 8, 2018. The study included 28 kidney transplant centers in the United States, including 386 low- to moderate-immune risk adult recipients of a living or deceased donor kidney transplant without delayed graft function or short-term rejection in the first week after transplant. Analyses were intention to treat. Analysis began September 2018 and ended June 2019.Patients were randomized to receive tacrolimus and mycophenolate mofetil with or without corticosteroids 7 days after transplant.Kidney allograft failure from any cause including death and allograft failure censored for patient death defined by the requirement for long-term dialysis or repeat transplant.Of 385 patients, 191 were assigned to withdraw from corticosteroids (mean [SD] age, 46.5 [12.1] years), and 194 patients were assigned to continued corticosteroids (mean [SD] age, 46.3 [12.6] years). The median (interquartile range) follow-up time was 15.8 (12.0-16.3) years after transplant. The adjusted hazard ratios of allograft failure from any cause including death was 0.83 (95% CI, 0.62-1.10; P = .19) and for allograft failure censored for patient death was 0.78 (95% CI, 0.52-1.19; P = .25) and did not differ between the patients assigned to withdraw from corticosteroids vs assigned to continued corticosteroids. Results were consistent in a per-protocol analysis among 223 patients who continued the trial-assigned treatment of corticosteroid withdrawal (n = 114) or corticosteroids (n = 109) through at least 5 years after transplant. The outcomes of trial participants in either treatment group did not differ from similarly treated contemporary registry patients who met trial eligibility criteria and were treated with the same immunosuppressive drugs.Long-term corticosteroids may not be necessary as part of a calcineurin-based multiple drug immunosuppressive regimen in low- to moderate-immune risk kidney transplant recipients.
Liraglutide, the Synthetic Glucagon-like Peptide-1 Receptor Agonist, Improves Insulin Sensitivity of 3T3-L1 Adipocytes and Affects the Kinetics of Mitogenic and Inflammatory Kinases
Authors: E. Mamontova, S. Michurina, N. Podkuychenko, E. Sorkina, I. Stafeev, M. Menshikov, M. Shestakova, Y.E. Parfyonova
Journal: Metabolism (2021)
Mitochondrial Dysfunctioning Induced by Hyperglycemia in the Liver Tissues of Diabetic Mice, TALLYHO/JngJ Strain and Ameliorative Action of a Small Peptide, SS31
Authors: Jasvinder Singh Bhatti, Kavya Tamarai, Ramesh Kandimalla, Maria Manczak, Xiangling Yin, Bhagavathi Ramasubramanian, Neha Sawant, Jangampalli Adi Pradeepkiran, Murali Vijayan, Subodh Kumar, P. Hemachandra Reddy
Journal: Metabolism (2021)
Screening for Asymptomatic Carotid Artery Stenosis in Adult Patients
Authors: Salomeh Keyhani, Eric M. Cheng
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 9822: Prognostic Significance of Serum Cholinesterase Level in Patients With Acute Decompensated Heart Failure: A Prospective Comparative Study With ALBI Score in Osaka Prefectural Acute Heart Failure Registry (OPAR)
Authors: Masahiro Seo, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Jun Nakamura, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Masatake Fukunami
Journal: Circulation (2019)

Backgrounds: Liver abnormalities have been reported as an important prognostic factor in patients with heart failure. ALBI (Albumin-Bilirubin) score was newly developed as a simple model to assess ...
Aberrant mature active mast cells in wasp venom anaphylaxis associated with clonal mast cell disorders
Authors: Leander De Puysseleyr, Jessy Elst, Didier Ebo, Margaretha Faber, Athina Van Gasse, Ine Decuyper, Christel Mertens, Michel Van Houdt, Margo Hagendorens, Katrien Vermeulen, Zwi Berneman, Vito Sabato
Journal: Journal of Allergy and Clinical Immunology (2021)
Leaked government white paper ends England’s NHS internal market and returns power to health secretary
Authors: Andy Cowper
Journal: BMJ (2021)

The government’s health and care white paper, which forms its legislative plans for the NHS in England, was revealed on 5 February 2021 by the Health Policy Insight website.12

Doctors’ attitudes to NHS politics and policy making vary widely, as does their interest in them. Quite a few doctors choose to ignore the politics of the system and to deliver their best care in the system as it is. And for doctors in Wales, Scotland, and Northern Ireland the government proposals will not make any difference because the NHS in those nations is organised differently.

For doctors in England, however, the proposed legislation is relevant because it contains significant changes to the current system. It is also different because many, although not all, of these changes were requested by the English NHS’s leadership.

There are two main changes in the proposed new legislation. One is to reverse almost every aspect of the Health and Social Care Act 2012. The …
Characterization of T cell, B cell and Natural Killer Cell Subsets in COVID-19 Patients
Authors: Alena Rynda, Andrei Hancharou, Natalia Antonevich, Oxana Timohina, Yana Minich, Alena Halavach, Darya Babrukevich, Marina Dotsenko, Eduard Dotsenko, Lawrence Dubuske
Journal: Journal of Allergy and Clinical Immunology (2021)
Negotiating mental health amongst transgender parents in Australia
Authors: Rosie Charter, Jane Ussher, Janette Perz, Kerry Robinson
Journal: International Journal of Transgender Health (2021)

Many transgender (trans) parents experience challenges related to their mental health, which can affect and impact on their experiences of parenting, however there is scant research on how Australian trans parents contextualize and experience their mental health, the support they receive for it, and impacts within the family context.The present study aims to address these gaps in the literature, through examining how Australian trans parents contextualize and experience issues around their mental health, and their experience of formal and informal support for their mental health?This study aimed to explore these experiences, through a qualitative research design using online open-ended survey data and one-on-one interviews, with 66 trans parents, aged 24-67 years old. Data was analyzed using thematic analysis.Many participants reported significant challenges in relation to their mental health: such as depression, anxiety, and suicidal ideation, which reportedly made parenting challenging. However, participants reported that gender affirmation as well as family and social support had a positive impact on their mental health. The majority of participants reported feeling they had to educate their therapist, that they were pigeon-holed by their gender identity or, had concerns about confidentiality. However, some participants expressed positive interactions with therapists, particularly therapists specializing in, or knowledgeable of, trans health.The results reinforced the need for mental health professionals and associated services to be competent in treating trans parents and reiterated the positive impact of family and social support, as well as support for gender affirmation, on the mental health of trans parents and their ability to parent.
Mitohormesis in Hypothalamic POMC Neurons Mediates Regular Exercise-Induced High-Turnover Metabolism
Authors: Gil Myoung Kang, Se Hee Min, Chan Hee Lee, Ji Ye Kim, Hyo Sun Lim, Min Jeong Choi, Saet-Byel Jung, Jae Woo Park, Seongjun Kim, Chae Beom Park, Hong Dugu, Jong Han Choi, Won Hee Jang, Se Eun Park, Young Min Cho, Jae Geun Kim, Kyung-Gon Kim, Cheol Soo Choi, Young-Bum Kim, Changhan Lee, Minho Shong, Min-Seon Kim
Journal: Cell Metabolism (2021)